Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down

The company has appointed Edward Dulac as its new CFO, executive vice president and treasurer. He will assume his new role with effect from Jul 22, 2024. Year to date, shares of Intellia have plunged 24.8% compared with the industry's decline of 4.6%. Intellia is a genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. NTLA-2001 is part of the company's ...